The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort. - Tariot PN; Lopera F; Langbaum JB; Thomas RG; Hendrix S; Schneider LS; Rios-Romenets S; Giraldo M; Acosta N; Tobon C; Ramos C; Espinosa A; et al. (Alzheimer's & dementia (New York, N. Y.), 2018)